‘Fail First’ Requirement In ACNU Proposal Prompts Adverse Reactions Across US Drug Industry
Executive Summary
PhRMA captures tone of its comments saying “proposed rule might play an important role” in making more drugs available OTC. AAM also references gauntlet, saying proposed pathway “would, in theory, broaden the types of nonprescription drugs available to consumers.” CHPA discusses same concerns as well as additional questions for FDA.
You may also be interested in...
Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers
“Nonprescription Drug Product with an Additional Condition” for OTC use proposed rule would add to drug firms’ workloads for some OTC switches. Along with NDAs, sponsors would need to show a DFl isn’t sufficient to ensure a consumer can appropriately self-select and use a drug OTC and how an “additional condition” system would work.
Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products
Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.
Improving US FDA Food Programs Starts At Top, Former Senior Agency Officials Say
Former acting commissioner Stephen Ostroff and Sharon Lindan Mayl, previously a senior advisor to FDA commissioner on food programs, say Reagan-Udall report was accurate in finding that establishing food program leadership with defined authorities is key to improving the programs, which include regulation of supplement manufacturing and marketing.